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ABSTRACT
The MDM2 oncoprotein has been shown to inhibit p53-mediated
growth arrest and apoptosis. It also confers growth advantage to
different cell lines in the absence of p53. Recently, the ability of MDM2
to arrest the cell cycle of normal human fibroblasts has also been
described. We report a novel function for this protein, showing that
overexpression of MDM2 promotes apoptosis in p53-deficient, human
medullary thyroid carcinoma cells. These cells, devoid of endogenous
MDM2 protein, exhibited a significant growth retardation after stable
transfection with mdm2. Cell cycle distribution of MDM2 transfec-
tants [medullary thyroid tumor (MTT)-mdm2] revealed a fraction of
the cell population in a hypodiploid status, suggesting that MDM2 is
sufficient to promote apoptosis. This circumstance is further demon-
strated by annexin V labeling. MDM2-induced apoptosis is partially
reverted by transient transfection with p53 and p19ARF. Both MTT
and MTT-mdm2 cells were tumorigenic when injected into nude mice.
However, the percentage of apoptotic nuclei in tumor sections derived
from MDM2-expressing cells was significantly higher relative to that
in the parental cell line. MDM2-mediated programmed cell death is
at least mediated by a down-regulation of the antiapoptotic protein
Bcl-2. Protein levels of caspase-2, which are undetectable in the pa-
rental cell line, appear clearly elevated in MTT-mdm2 cells.
Caspase-3 activation does not participate in MDM2-induced apopto-
sis, as determined by protein levels or poly(ADP-ribose) polymerase
fragmentation. The results observed in this medullary carcinoma cell
line show for the first time that the product of the mdm2 oncogene
mediates cell death by apoptosis in p53-deficient tumor cells. (Endo-
crinology 141: 420–429, 2000)
MEDULLARY THYROID carcinoma (MTC) is a neu-roendocrine tumor of the parafollicular C cells that
accounts for up to 10% of all thyroid tumors (1). One fourth
of all MTC appear to be genetically determined and are
associated with inherited clinical syndromes (multiple en-
docrine neoplasia 2A and 2B and familial MTC). The re-
maining cases of MTC are sporadic and therefore occur as the
consequence of somatic alterations caused by both genetic
and epigenetic factors (2). Established cell lines from human
and animal MTC tumors provide a valuable system to an-
alyze genes involved in the development of this neoplasia.
Human medullary thyroid tumor cells (MTT), recently char-
acterized in our laboratory (3), show all of the major prop-
erties described for MTC cells. They immunoreact with spe-
cific calcitonin antibodies (our unpublished observations)
and express somatostatin and somatostatin receptors 2, 3, 4,
and 5 (4). The transformed phenotype of these cells is at least
due to a loss of expression of the tumor suppressor gene p53
and a genetic deletion involving exon 11 of the ret protoon-
cogene (3).
The oncogenic potential of the murine double-minute-2
(mdm2) gene was originally detected in spontaneously trans-
formed murine fibroblasts (5). Thereafter, genetic amplifica-
tion of the mdm2 gene was detected in different human tu-
mors and cell lines (6, 7). More recently, the oncogenic
function of the mdm2 gene product (MDM2) has also been
determined in transgenic mice expressing MDM2 in the
mammary gland. These animals, which show major alter-
ations of the cell cycle, have a high incidence of breast tumors
(8). Coimmunoprecipitation experiments determined that
MDM2 physically interacts with the p53 tumor suppressor
gene product (9), leading to the idea that, as described for
proteins such as the simian virus 40 large T antigen or the
papillomavirus E6 protein, the oncogenic potential of MDM2
is based on its ability to bind to and inactivate p53. Thus, the
inactivation of p53 function by MDM2 results in the abro-
gation of both p53-mediated cell cycle arrest and apoptosis.
Recent findings indicate that inactivation of p53 by MDM2
occurs by promoting the degradation of the tumor suppres-
sor protein through the ubiquitin-proteasome pathway (10,
11). In addition, the discovery that p53 is able to transcrip-
tionally activate the expression of mdm2 (12) led to the hy-
pothesis that a feedback autoregulatory loop provides a pre-
cise time frame for p53 signaling to regulate the cell cycle.
MDM2 also interacts with other proteins important in the
regulation of cell cycle transition, such as the retinoblastoma
gene product, the TATA-binding protein, the transcription
factor E2F, and the INK4a-ARF tumor suppressor gene prod-
uct p19ARF (13–15).
Recently, studies in NIH-3T3 fibroblasts revealed that
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MDM2 arrests the cell cycle, causing a specific inhibition of
G0/G1-S transition (16). In the present report we demonstrate
that MDM2 is sufficient to promote apoptosis in the MTT cell
line. Transfection of these cells with mdm2 resulted in the
isolation of clones that constitutively express MDM2. These
clones exhibit a growth retardation compared with the pa-
rental cell line. Cell cycle analysis and annexin V labeling
show a significant fraction of these MDM2 transfectants un-
dergoing apoptosis, thus providing a direct link between
MDM2 expression and programmed cell death.
Materials and Methods
Cell culture
The human MTC cell line MTT (3) was maintained in RPMI 1640
medium supplemented with 10% FBS, 2 mm glutamine, 100 mg/ml
sodium pyruvate, 100 U/ml penicillin, and 100 mg/ml streptomycin.
The human follicular thyroid carcinoma cell lines FRO, ARO, and NPA
were provided by Dr. J. A. Fagin (University of Cincinnati, Cincinnati,
OH) and Dr. Juillard (University of California, Los Angeles, CA). They
were maintained in the same conditions as those used for the MTT cells.
Human breast cancer MCF-7 cells were grown in DMEM supplemented
with 10% FBS, 2 mm glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin.
Plasmids and transfections
pCMDM2 was constructed by ligation of the human mdm2 comple-
mentary DNA (cDNA) (6) containing the complete open reading frame
into the BamHI site of the pCDNA3 eukaryotic expression vector (In-
vitrogen BV, Leek, The Netherlands). DNAs (pCMDM2 and pCDNA3)
were transferred into MTT cultures (106 cells/plate) using lipofectin,
following the manufacturer’s directions. For all experiments reported,
early passage cells (,10) were used. Optimum conditions for DNA
transfer were found by mixing equal amounts of lipofectin reagent and
DNA (2–10 mg) and maintaining the lipid-DNA complex in serum-free
medium cultures for 8–12 h. G418 (200 mg/ml) was added to the cultures
for selection. Nuclear extracts from transient experiments were collected
72 h after transfection. For the scoring colony formation assay, 4 weeks
after transfection, colonies were fixed in 70% methanol and stained with
0.5% crystal violet. In these experiments, a retroviral construct express-
ing wild-type human p53 (17), and an expression vector carrying the
p19ARF cDNA (18) were also used. For establishment of constitutive
transfectants, resistant colonies were either isolated from the plates
individually or pooled and expanded to generate cell lines. Unless
otherwise indicated, reagents were purchased from Life Technologies,
Inc. (Gaithersburg, MD).
Cell growth and tumorigenicity assays
Cells (2 3 104) were seeded in 6-cm plates, and the number of viable
cells was determined every 24 h for 4 consecutive days by the trypan blue
dye exclusion test. Experiments were performed in triplicate. For tu-
morigenicity assays, 5 3 106 cells from each cell line were trypsinized,
collected in 100 ml PBS, and injected sc into nude mice. Tumor formation
was monitored weekly, and tumorigenicity was scored as the number
of tumors per site after 4 weeks.
Detection of apoptosis
To determine cell cycle distribution, asynchronous cultures were
trypsinized and fixed in 70% ethanol. Cells were pelleted, resuspended
in PBS, and stained with propidium iodide. Stained samples were an-
alyzed in a FACScan flow cytometer (Becton Dickinson, San Jose, CA).
Histograms containing at least 10,000 events were generated using Lysis
II software (Becton Dickinson and Co.).
Apoptosis was also monitored by annexin V labeling and fluores-
cence microscopy (19). Cells were washed with PBS and then treated
with annexin V-fluorescein (Roche Molecular Biochemicals, Mannheim,
Germany) for 15 min. After a 488-nm excitation, green fluorescence was
visualized and recorded at 515 nm. Phase contrast microscopic images
from the same preparations were also obtained.
Apoptotic cells from tumor sections were identified by TUNEL (ter-
minal deoxynucleotidyltransferatse-mediated deoxy-UTP-biotin nick
end labeling) staining (20), with minor modifications, as previously
described (21).
Northern analysis
Total RNA was extracted from guanidinium isothyocianate cell ly-
sates (22) with phenol-chloroform and isopropanol precipitation. RNA
samples (20 mg) were separated by 1% agarose electrophoresis under
denaturing conditions (1.1 m formaldehyde and 50% formamide) and
transferred to Nytran filters (Schleicher & Schuell, Inc., Keene, NH).
Prehybridization and hybridization were performed at 42 C for 6 and
24 h, respectively, in a buffer containing 50 mm Na2HPO4 (pH 6.5), 5 3
SSC (standard saline citrate), 0.2% SDS, 5 3 Denhardt’s solution, and
50% formamide. Blots were washed three times at room temperature in
2 3 SSC-0.1% SDS and twice at 42 C in 0.1% SSC-0.1% SDS. A 1.6-kb
human mdm2 probe, obtained after SalI/BamHI digestion of pcMDM2,
was used for hybridization. DNA fragments were purified using Ge-
neclean (BIO 101, La Jolla, CA) and labeled with [a-32P]deoxy-CTP by
random priming. Specific activity was usually about 5 3 108 cpm/mg.
To assess equal loading of the samples, the same blots were hybridized
with a b-actin probe.
RT-PCR amplification
MTC tumor samples were provided by Drs. E. Mato and X. Matias-
Guiu (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain). Total RNA
from the tumor samples was extracted as described above (22). RNA
preparations (1 mg) were reverse transcribed using Moloney murine
leukemia virus reverse transcriptase (Pharmacia Biotech, Piscataway,
NJ) for first strand synthesis. Aliquots of the reactions were then used
for PCR amplification using Taq polymerase (Perkin-Elmer Corp.,
Norwalk, CT). Forward and reverse primers for mdm2 amplification
were 59-GCTGAAGAGGGCTTTGAT-39 and 59-TGGTGTAAAGGAT-
GAGCT-39. Amplification was carried out for 40 cycles, and PCR cycle
parameters were: denaturation at 94 C for 1 min, annealing at 55 C for
1 min, and extension at 72 C for 1 min. Control amplification of glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) was performed with
the following forward and reverse primers: 59-GACCCACATCGCTCA-
GAC-39 and 59-TTCTCCATGGTGGTGAAG-39. Amplification was per-
formed in 40 cycles with these PCR cycle parameters: denaturation at 94
C for 1 min, annealing at 62 C for 30 sec, and extension at 72 C for 90
sec. PCR products were separated and visualized in ethidium bromide-
stained 2% agarose gels.
Western analysis
Nuclear extracts were obtained as previously described (23). Equal
amounts of nuclear proteins (20 mg) were subjected to SDS-PAGE and
transferred to nitrocellulose membranes (Schleicher & Schuell, Inc.,
Keene, NH). After blocking membranes with 5% low fat dry milk in
Tris-buffered saline-0.05% Tween-20, immunodetection of MDM2 was
performed using a commercial monoclonal antibody (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA). After incubation with a horseradish
peroxidase-conjugated secondary antibody, immunoreactive proteins
were visualized by Western blotting luminol reagent (Santa Cruz Bio-
technology, Inc.). Starting from total protein extracts, similar protocols
were used to detect the apoptosis-related proteins Bcl-2, Bcl-x, caspase-2,
caspase-3, and receptor interactin protein (RIP), using antibodies ob-
tained from Transduction Laboratories (Lexington, KY). Poly(ADP-ri-
bose) polymerase (PARP) and actin antibody were purchased from
Santa Cruz Biotechnology, Inc.
Statistical analysis
Statistical significance among experimental groups was determined us-
ing Student’s t test. Differences were considered significant at P , 0.05.
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Results
The mdm2 protooncogene is not expressed in the MTT
cell line
We have previously reported that overexpression of p53 in
MTT cells causes a partial G1-specific arrest, as p53 clones are
able to partially overcome the G1 block and progress through
the cell cycle (3). In this study we have searched for cell cycle
regulatory pathways operating in this p53-null cell line and
analyzed the participation of the MDM2 oncoprotein.
We initially characterized the expression levels of mdm2 by
Northern analysis. To our knowledge, expression of mdm2
had never been tested in any thyroid-derived tumor cell line,
so we included a panel with three follicular tumor cell lines
(FRO, ARO, and NPA). Total RNA was extracted and hy-
bridized with a mdm2 cDNA probe. As shown in Fig. 1A, a
5.5-kb mdm2 transcript was detected in the three follicular
thyroid carcinoma cell lines. The mol wt for mdm2 messenger
RNA (mRNA) was as previously described (6). Expression
was maximum in FRO cells and was also detected in ARO
and NPA. However, expression of mdm2 was absent in MTT
cells.
The absence of mdm2 transcripts in the MTT cell line
prompted us to analyze whether this observation was re-
stricted to this particular cell line or could be extended to
other MTC samples. To address this question, RNA from
four MTC tumors was analyzed for the presence of mdm2 by
RT-PCR. Positive and negative control experiments included
NPA and MTT samples, respectively. Results show that none
of the tumors analyzed expressed mdm2, whereas a band of
the expected size was amplified from NPA cells. In all cases,
the integrity of the RNA samples was confirmed using prim-
ers for GAPDH (Fig. 1B).
Expression of mdm2 interferes with MTT cell growth
To analyze the participation of the mdm2 protooncogene in
the transformed phenotype of the MTT cell line, we intro-
duced an exogenous mdm2 gene to study the effect on cell
proliferation. A mammalian expression vector carrying the
human mdm2 cDNA in sense orientation was transfected by
lipofection into MTT cell line. A control experiment was
performed using empty vector (pCDNA3). G418 was added
to the cultures 48 h after transfection, and clonal selection
was maintained for 3 weeks. After that period, we observed
that the ability of individual colonies to progress was clearly
reduced in those cells receiving the mdm2 expression vector.
Moreover, outgrowing colonies from mdm2 transfections
were clearly smaller than those obtained with the empty
vector (Fig. 2, A and B). To quantify this observation, plates
were fixed with methanol and stained with crystal violet. As
a control for these experiments, two genes previously de-
scribed to act as negative regulators of cell growth were used:
p53, which has been shown to inhibit cell growth in this
particular cell line (3), and the INK4a tumor suppressor gene
p19ARF, which interferes with cell proliferation in many cell
lines (18). Results are summarized in Table 1. Compared with
the control transfections, expression of mdm2 decreased col-
ony formation about 3-fold. This reduction was similar to
that obtained with the tumor suppressor gene p19ARF. A
much greater effect was observed with a p53 expression
vector. These results indicate that overexpression of mdm2
has a negative effect on cell growth.
We next attempted to generate stable transfectants ex-
pressing mdm2. For this purpose, G418 resistant colonies
were isolated and expanded as clonal cell lines, designated
MTT-mdm2 clones (c1 to c5). To avoid clonal heterogeneity,
pools (-p) from the same transfection assays were also iso-
lated and analyzed in parallel. A control cell line (pC-MTT)
was originated by transfection of MTT cells with the empty
vector. MTT-mdm2 clones are viable and show major alter-
ations on cell morphology with respect to the parental cell
line (Fig. 2, C and D). Whereas asynchronous cultures of MTT
cells have a typical criss-cross pattern and fibroblast-like
morphology, MDM2 transfectants exhibit lower saturation
density values and appear more refringent under phase con-
trast microscopy. This morphology was different from that
produced by other genes tested in the assay that have a
negative effect on cell growth. They did not show the cell to
cell extensions found in p53-transfected cells (Fig. 2E), or the
spindle-shaped morphology of MTT cells transfected with
p19ARF (Fig. 2F).
Before further characterization, the expression levels of
FIG. 1. A, Expression of mdm2 in different follicular tumor thyroid
cell line (ARO, FRO, and NPA) and in the MTT human medullary
carcinoma cell line. Total RNA from the different cell lines was ex-
tracted, electrophoresed, and hybridized with a specific mdm2 cDNA
probe. Migration of the 28S ribosomal RNA is indicated. After expo-
sure, the same blot was stripped and hybridized with a b-actin probe
to assess equal loading of the RNA preparations. B, Detection of
mdm2 transcripts in human MTC tumors by RT-PCR. Total RNA
from MTT, NPA cells, and four human tumor samples was reverse
transcribed and amplified with specific primers. The sizes of the PCR
fragments are indicated. GAPDH was used from the same RT reac-
tions to assess the integrity of the preparations.
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mdm2 mRNA in MTT-mdm2 clones were analyzed by North-
ern blot (Fig. 3A). Specific transcripts corresponding to the
exogenous mdm2 were detected in MTT-mdm2 cells, whereas
hybridization was absent in those cells transfected with the
control vector. To confirm that detected transcripts encoded
for a MDM2 protein, nuclear extracts from MTT-mdm2-c1,
-c4, and -p1, which showed higher expression levels of
mRNA, were isolated, resolved by electrophoresis, and im-
munoblotted with a specific human MDM2 monoclonal an-
tibody. A polypeptide migrating at 90 kDa was observed in
all MTT-mdm2 transfectants (Fig. 3B). Protein accumulation
was maximum in MTT-mdm2-c1. These results confirmed
the presence of MDM2 and indicated that the exogenous
protein is efficiently translocated to the nucleus. To obtain an
estimation of the levels of protein achieved in MTT-mdm2
clones, nuclear extracts from MCF-7 were included in the
assay. The results show that MDM2 protein levels in MTT-
mdm2 clones were comparable to those in cells naturally
overexpressing MDM2 (24).
We next quantified the negative effect on cell growth by
determining the growth rate of MTT cells transfected with
either mdm2 or the control vector. Cells were seeded, and the
number of viable cells was determined for 4 consecutive days
(Fig. 3C). The results demonstrated a significant growth re-
tardation induced by MDM2. After 4 days in culture, the total
cell number of MDM2 transfectants was up to 40% lower
than that obtained for the parental cell line. This inhibitory
effect, although variable, was observed in both individual
clones and pooled cultures.
MDM2 promotes apoptosis in MTT cells
To analyze the cellular mechanisms responsible for MDM2
interference with MTT cell growth, we analyzed cell cycle
distribution of MTT cells transfected with mdm2. Asynchro-
nous cultures from those clones positive in the Western blot
were collected and analyzed by flow cytometry. Histograms
from two individual clones and one pool are shown (Fig. 4),
and data summarized in Table 2. Cell cycle distribution of
MTT cells, transfected with the control vector, showed values
similar to the previously described histograms for the pa-
rental, untransfected MTT cells (3). MTT-mdm2 clones con-
sistently showed a fraction of hypodiploid cells (ranging
from 35–49%), with a DNA content below 2N (sub-G0/G1).
This distribution is characteristic of apoptotic cells (25) and
therefore suggests that MDM2 promotes cell death in these
cells. It is remarkable that apart from this sub-G0/G1 fraction,
the remaining cells are distributed along the cell cycle almost
normally, although G2-M values were slightly lower than
those measured in MTT cells.
We further confirmed that hypodiploid cells detected by flow
TABLE 1. Effect of mdm2 expression on MTT colony formation
Vector Colonies
pCDNA3 400 6 17
p19ARF 190 6 16a
pC-mdm2 155 6 23a
pZ-p53 sense 20 6 5a
MTT cells were transfected with 10 mg of the different plasmids
using the lipofection technique. G-418-resistant cells were allowed to
grow for 3 weeks, then fixed and stained with crystal violet to deter-
mine colony number. Experiments were performed in triplicate. Av-
erage values and SEs are shown.
a Statistically significant vs. pCDNA3 (P # 0.01).
FIG. 2. Morphological appearance of
outgrowing MTT (A) and MTT-mdm2
colonies (B). Phase contrast pictures of
asynchronous cultures derived after se-
lection with G418 of MTT cells trans-
fected with control vector (C) and ex-
pression vectors for MDM2 (D), p53 (E),
and p19ARF (F).
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cytometry corresponded to cells undergoing apoptosis. For that
purpose, MTT and MTT-mdm2-c1 cells, which exhibited the
highest sub-G0/G1 fraction, were collected and treated with
annexin V. This protein, which specifically interacts with phos-
phatidylserine exposed in the outer layer of the plasma mem-
brane, is a valuable marker for detection of apoptotic cells (19).
Data obtained from fluorescence detection of MTT and MTT-
mdm2-c1 together with the phase contrast microscopic images
of the same fields are shown (Fig. 5). Apoptosis was clearly
detected in MTT-mdm2 cells (Fig. 5, A and B), whereas it was
virtually absent in MTT samples (Fig. 5, C and D). Staining with
propidium iodide indicated that necrotic cells were almost ab-
FIG. 3. Constitutive expression of MDM2 results in growth retardation of MTT cells. A, Detection of mdm2 expression by Northern blot. RNA
from MTT cells, those transfected with the control vector (pC-MTT), and those transfected with pCMDM2 (MTT-mdm2) were extracted,
electrophoresed, and hybridized with a mdm2 cDNA probe. After stripping, the same blot was hybridized with a b-actin probe. The mobilities
of the 28S and 18S ribosomal RNAs are indicated. B, Immunodetection of MDM2 in MTT-mdm2 clones. Nuclear extracts were separated by
SDS-PAGE and probed with MDM2 antibodies. Mol wt markers are shown on the right. MCF-7 cell nuclear extracts were used as a positive
control. C, Growth profiles of MTT cells and MTT-mdm2 clones. The average values of viable cell number are represented. Experiments were
performed in triplicate.
FIG. 4. Flow cytometric analysis of
asynchronous MTT and MTT-mdm2
clones. Cells were fixed with ethanol,
stained with propidium iodide, and an-
alyzed by FACScan. Histograms from
the parental cell line, two individual
mdm2 transfected clones (c1 and c4),
and one pool (p1) are represented.
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sent in both preparations (not shown). Quantification of dif-
ferent fields indicated that the fraction of apoptotic cells was
about 40% of the total cell population, thus providing a good
correlation among growth retardation profiles, cell cycle his-
tograms, and apoptosis.
MDM2 induction of apoptosis is partially reverted by
wild-type p53
In an attempt to understand whether MDM2 induction of
apoptosis is related to the p53 defect of MTT cells, a series of
transient transfection experiments was performed. Both
MTT and MTT-mdm2 (clone c1) cells were seeded and then
transfected with an expression vector for wt p53. A parallel
experiment was also performed using an expression vector
for the p19ARF, and finally, both vectors were also cotrans-
fected. In all cases, cells were collected 72 h after transfection
to determine the percentage of apoptotic cells and cell cycle
distribution by flow cytometry.
Control experiments with an empty expression vector gave
sub-G0/G1 values similar to those obtained previously (Table
1). After transfection with p53, the percentage of the sub-G0/G1
was significantly lower, indicating that the tumor suppressor
partially reverts MDM2 induction of apoptosis (Table 3). This
observation parallels the increase in the percentage of cells in
G0/G1 phase. Similar data were obtained after transfection with
p19ARF, although in this case, cells were not clearly arrested in
G0/G1. When both constructs were contransfected, results were
comparable to those obtained with p53 alone, indicating that the
effect of those genes is not additive.
Tumors derived from mdm2-expressing cells show an
increased number of apoptotic nuclei
We next evaluated whether the negative effect induced by
MDM2 on cell growth and the ability to promote apoptosis
were extended when MTT cells were allowed to form tumors
in vivo. MTT and MTT-mdm2 (clone 1) cells were injected sc
TABLE 3. Cell cycle distribution of MTT-mdm2 cells transfected with p53, p19ARF, and p53/p19ARF
Sub-G0/G1 G0/G1 S G2/M
MTT-mdm2-c1 46.29 6 0.70 35.06 6 0.83 12.54 6 1.09 6.11 6 0.79
MTT-mdm2/p53 33.48 6 0.87a 42.42 6 0.46 12.44 6 0.83 11.44 6 0.64
MTT-mdm2/p19ARF 36.47 6 1.21a 37.37 6 0.63 15.73 6 0.86 10.64 6 0.99
MTT-mdm2/p53 1 p19ARF 32.74 6 1.01a 43.93 6 0.64 12.10 6 0.73 11.33 6 0.82
Samples were collected and fixed, and cell cycle was analyzed by FACSscan as described in Materials and Methods. Experiments were
performed in triplicate. Average values and SEs are represented.
a Statistically significant vs. MTT-mdm2-c1 (P # 0.01).
TABLE 2. Cell cycle distribution of MTT cells transfected with mdm2
Sub-G0/G1 G0/G1 S G2/M
MTT 1.57 6 0.17 47.34 6 0.20 27.08 6 0.43 24.01 6 0.30
MTT-mdm2-c1 49.63 6 0.87a 34.94 6 0.54 9.25 6 0.13 6.18 6 0.24
MTT-mdm2-c4 46.54 6 0.72a 35.21 6 0.95 11.65 6 0.37 6.60 6 0.19
MTT-mdm2-p1 33.06 6 0.25a 41.75 6 1.18 14.32 6 0.29 10.87 6 0.26
Samples were collected and fixed, and cell cycle was analyzed by FACSscan as described in Materials and Methods. Experiments were
performed by triplicate. Average values and SEs are represented.
a Statistically significant vs. MTT (P # 0.01).
FIG. 5. Detection of MDM2-induced
apoptosis in MTT cells. Apoptosis was
monitored by annexin V and fluores-
cence microscopy. Phase contrast mi-
croscopy pictures of MTT-mdm2 (A) and
MTT cells (C) were analyzed by fluores-
cence at 515 nm (B and D, respectively).
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into nude mice, and tumor formation scored after 4 weeks.
As shown in Table 4, both MTT and MTT-mdm2 cells gave
rise to tumors in 100% of the cases. Tumors derived from
MTT-mdm2 cells emerged later, although this difference was
not significant, indicating that the negative interference of
MDM2 with cell growth does not reverse the transformed
phenotype of these cells.
To rule out the possibility that the lack of effect could
be due to a loss of mdm2 expression during tumor devel-
opment, samples were analyzed for the presence of MDM2
protein by immunohistochemistry. Slide preparations
from MTT and MTT-mdm2 tumors were fixed and incu-
bated with MDM2 antibodies. As expected, tumors de-
rived from the parental cell line did not show immuno-
staining. However, MTT-mdm2 tumors showed positive
staining, indicating that MDM2 is efficiently expressed in
the tumor (data not shown).
We next examined whether mdm2, expressed in the tumors
derived from MTT-mdm2 cells was also able to promote
apoptosis in vivo. For this purpose, tumor sections were an-
alyzed for the presence of apoptotic nuclei by TUNEL assay
(Table 3). Tumors derived from the MTT cell line showed a
very low percentage of TUNEL-positive cells (0.3%). How-
ever, in those tumors derived from MTT-mdm2 cells, the
percentage of apoptotic nuclei increased almost 20-fold
(5.3%). These results unambiguously confirm the ability of
the MDM2 protein to induce apoptosis in MTT cells, both in
vivo and in vitro.
Bcl-2 and caspase-2 participate in MDM2-
induced apoptosis
Molecular mechanisms underlying MDM2-mediated ap-
optosis in MTT cells were explored. We reasoned that if
MDM2 is able to induce apoptosis in MTT cells, specific
antiapoptotic pathways operating in the parental cell line
should be shut down in those cells transfected with mdm2. To
test this hypothesis, we measured protein levels of Bcl-2, a
protein that suppresses programmed cell death in many cell
lines (26). Using specific antibodies for Bcl-2, we detected an
immunoreactive band in the parental MTT cells (Fig. 6). In
those clones transfected with mdm2, Bcl-2 protein levels were
almost undetectable. Only after long exposure of the auto-
radiographs could a faint band be visualized, indicating a
strong down-regulation of Bcl-2 induced by mdm2. We also
measured protein levels of Bcl-x. The bcl-x gene is related to
bcl-2, although proteins encoded by this locus can function
independently of Bcl-2. Two products, generated by alter-
native splicing, arise from the bcl-x gene: Bcl-xL and Bcl-xS.
Whereas the former also inhibits apoptosis in some cell sys-
tems, Bcl-xS promotes cell death (27). In MTT cells, Bcl-x was
present in asynchronous cultures and, upon transfection
with mdm2, no consistent modifications of Bcl-x were ob-
served. In some clones, a slight up-regulation of Bcl-x was
detected, whereas in most cases no major differences were
found.
It was recently shown that Bcl-2 regulates apoptotic
cascades mediated by caspase-3 and caspase-2 (28), so we
analyzed whether any of these cystein proteases could be
detected in MTT-mdm2 cells (Fig. 7). We used antibodies
for caspase-2 and caspase-3 and probed membranes con-
taining total protein extracts from MTT and MTT-mdm2
FIG. 6. MDM2 down-regulates protein levels of Bcl-2. Protein ex-
tracts from MTT cells and MTT cells transfected with mdm2 (clones
c1, c4, and p1) were separated by SDS-PAGE and probed with specific
antibodies for Bcl-2 and Bcl-x. Equal loading of the samples was
assessed using an actin antibody. Mol wt marker migration is indi-
cated.
TABLE 4. Effect of mdm2 expression on tumorigenicity and
population of TUNEL-positive cells from the tumors
Vector Tumors in nude mice % Apoptotic cells
pCDNA3 6/6 0.3
pcMDM2 6/6 5.3
Tumorigenicity is expressed as the number of tumors/sites injected
and was scored 4 weeks after transfection. The percentage of apo-
ptosis was determined by TUNEL assay.
FIG. 7. Caspase-2 is up-regulated in MTT cells transfected with
mdm2. Protein extracts from MTT cells and MTT cells transfected
with mdm2 (clones c1, c4, and p1) were separated by SDS-PAGE and
probed with specific antibodies for caspase-2, caspase-3, RIP, PARP,
and actin. Mol wt marker migration is indicated.
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cells. In the parental cell line, caspase-2 was undetectable.
However, it was clearly up-regulated in cell lines trans-
fected with mdm2. We next determined protein levels of
caspase-3. As shown, we were unable to detect the pres-
ence of this protease in extracts from either MTT or MTT-
mdm2 cell lines, although it was clearly visualized in
extracts from Jurkat cells (not shown). To further rule out
a participation of caspase-3, we determined the proteolytic
cleavage of PARP, an enzyme involved in DNA repair, and
a common substrate of caspase-3 (29). Total extracts were
subjected to Western blot analysis with an antibody
against PARP. As expected, only the uncleaved, 115-kDa
isoform was observed in both MTT and mdm2 transfected
cells.
Taken together these results point to a mechanism involv-
ing caspase-2 and independent of caspase-3. These mecha-
nisms have been described in some apoptotic pathways, such
as those mediated by tumor necrosis factor-a (TNFa) (30). To
explore whether a similar mechanism could be acting in
MTT-mdm2 cells, we determined protein levels of RIP (31),
an adapter molecule involved in apoptotic pathways involv-
ing caspase-2 independently of caspase-3. Total protein ex-
tracts from the MTT cell line and from cells transfected with
mdm2 were obtained. Western blot was carried out using an
antibody against RIP. As shown in Fig. 7 an immunopositive
band corresponding to RIP (74 kDa) was observed. However,
we detected the same amount of the immunoreactive band
in both MTT and MTT-mdm2 clones, suggesting that acti-
vation of caspase-2 may occur through a different apoptotic
pathway.
Discussion
The results presented in this study provide evidence for a
novel function mediated by MDM2 and indicate for the first
time that this oncoprotein promotes apoptosis in a human
MTC cell line characterized by the presence of a genetic
rearrangement of the p53 locus (3). These results together
with those showing the ability of MDM2 to arrest the cell
cycle of normal fibroblasts (16) indicate that the product of
the mdm2 protooncogene may also interfere negatively with
cell proliferation. Several studies have previously demon-
strated that MDM2 promotes tumorigenesis when it is over-
expressed. It has been shown to cooperate with ras in the
transformation of rat embryo fibroblasts (32) and to induce
neoplastic conversion of murine immortalized cells (33).
Likewise, MDM2 is able to prevent p53-mediated apoptosis
in some tumor cell lines (34) as well as G1 cell cycle arrest
even in the absence of p53 (35).
These opposite functions support the idea that, as previ-
ously described for other genes such as c-myc (36), E1A (37),
or cyclin D1 (38, 39), some regulatory proteins could be
involved in both tumorigenesis and apoptosis depending on
the cellular environment. MDM2 should, then, be considered
as a multifunctional regulator of cell cycle progression,
whose effect on cell growth may be dependent not only on
p53, but also on other known or unknown regulatory
proteins.
Expression of mdm2 is found in the three follicular tumor
thyroid cell lines tested. It is important to mention that ex-
pression of mdm2 is higher in FRO cells, in which no alter-
ations of p53 have been described (40). Both ARO and NPA
carry a mutation of the p53 gene and would render protein
products for this tumor suppressor unable to trans-activate
mdm2. Nevertheless, differences in mdm2 expression are not
dramatic among the three cell lines tested, suggesting that
other regulatory genes, apart from p53, participate in mdm2
transcription. Of special interest is the observation that mdm2
transcripts are not detected in any of the four MTC tumor
samples analyzed. Whether there is a correlation between
lack of mdm2 expression and this particular tumor type re-
quires further investigation and is currently being studied.
Cell growth profiles and cell cycle histograms of MTT-
mdm2 clones indicate that whereas in some cells expres-
sion of mdm2 promotes apoptosis, others not only remain
viable, but also progress along the cell cycle. The fact that
the same results have been observed in pools and indi-
vidual clones rule out the possibility of an artifact caused
by an inappropriate integration of mdm2 during transfec-
tion. Rather, the effects must be explained considering that
in MTT cells, MDM2 may be also activating some of the
previously described pathways that favor cell growth (41).
It is also possible that the threshold of MDM2 expression
dictates the decision of a given cell to either enter the cell
cycle or commit programmed cell death. In this regard, it
may be important that a correlation was observed between
mdm2 expression levels and the percentage of apoptosis in
the asynchronous cultures. Expression is maximum in the
individual clones, where a higher percentage of apoptosis
is found.
The results reported here have been observed at both early
and late passages. To date, no significant decrease in the
expression of mdm2 has been observed in our cultures. The
fact that MDM2 levels are maintained, and apoptosis is also
detected at late passages rule out the possibility that the
deleterious effect of MDM2 may be limited to early events in
the transfection assays, where high amounts of the protein
are expressed inappropriately. Rather, we believe that
MDM2 physiologically regulates and promotes apoptosis in
these cells. Moreover, apoptosis mediated by MDM2 may be
partially reverted by exogenous expression of both p53 and
p19ARF, as determined by transient transfection analysis. In
the case of p53, we have previously demonstrated that the
tumor suppressor gene causes a G1 arrest in these cells (3),
and here we observed that even in the presence of MDM2,
p53 partially arrest MTT cells in that phase of the cell cycle,
thereby preventing them from undergoing apoptosis. On the
other hand, the ability of p19ARF to partially reverse MDM2-
induced apoptosis is in keeping with the observation that the
product of the INK4a locus is able to bind to and promote the
degradation of MDM2 (14, 15).
In agreement with results published for the MTC cell line
TT and MTC tumors (42), we have clearly detected expres-
sion of Bcl-2 in MTT cells, suggesting that the Bcl-2 onco-
protein may contribute to the pathogenesis of these tumors
and transformed cells. Here we show that apoptosis induced
by MDM2 is accompanied by down-regulation of Bcl-2, thus
allowing cell death to progress. This together with the acti-
vation of caspase-2 suggest that, as previously described for
other cell systems (43), both pathways interact. Nevertheless,
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in our Western assays with caspase-2 antibodies, we detect
immunoreactive forms corresponding to the procaspase
form and have been unable to detect any band corresponding
to any cleaved form of this protease. Results also show that
caspase-3 is not activated in MTT-mdm2 cells, as 1) this
protease in not detected in protein extracts; and 2) fragmen-
tation of PARP, a well characterized substrate for caspase-3,
is not cleaved in MTT-mdm2 cells. This points to an apoptotic
cascade dependent on caspase-2, although caspase-3 inde-
pendent, such as those described for cell death mediated by
TNFa. It has been shown that TNF binding to its receptor
results in the clustering of receptor death domains. Then, the
adapter protein RIP binds through its own death domain to
the clustered receptor death domain, and this complex joins
another adapter molecule, RAIDD/CRADD (44, 45). Upon
recruitment by CRADD, caspase-2 drives its activation
through self-cleavage. Two pieces of evidence suggest that a
different pathway is acting in MTT cells transfected with
MDM2. First, protein levels of RIP were similar in control and
MDM2-expressing cells, and as mentioned, we have been
unable to detect a cleaved form of caspase-2.
Previous reports (8, 14) and the observation described here
definitively indicate that the response to MDM2 overexpres-
sion is cell specific. Therefore, it is important to determine the
cellular environment in which MDM2 is able to induce
apoptosis, and in this context, the medullary carcinoma cell
line MTT constitutes an excellent system for these studies. As
these cells are naturally devoid of p53 (3), other regulatory
proteins functionally related to MDM2 should be carefully
analyzed. Potential candidates for this analysis include the
p53 homolog p73 (46), an antiproliferative protein whose
function is modified by MDM2 (47, 48).
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